Research Center of Neurology, Volokolamskoye shosse 80, 125367, Moscow, Russia.
Biological Department, Saint Petersburg State University, Universitetskaya Emb. 7/9, 199034, St Petersburg, Russia.
Eur J Pharmacol. 2020 Nov 5;886:173457. doi: 10.1016/j.ejphar.2020.173457. Epub 2020 Aug 1.
Multiple organ failure in COVID-19 patients is a serious problem which can result in a fatal outcome. Damage to organs and tissues, including general lung dysfunction, develops as a consequence of ischemia, which, in turn, is caused by thrombosis in small blood vessels and hypoxia, leading to oxidative stress and inflammation. Currently, research is underway to screen existing drugs for antioxidant, antiplatelet and anti-inflammatory properties. Having studied the available publications concerning the mechanisms of damage to tissues and organs of patients with COVID-19, as well as the available treatment strategies, we propose to investigate salicyl-carnosine as a potential drug for treating COVID-19 patients. In a recent study, we described the drug's synthesis procedure, and showed that salicyl-carnosine possesses antioxidant, anti-inflammatory, and antiplatelet effects. Therefore, it can simultaneously act on the three pathogenetic factors involved in tissue and organ damage in COVID-19. Thus, we propose to consider salicyl-carnosine as a potential drug for the treatment of patients with severe cases of COVID-19 infection.
新型冠状病毒肺炎（COVID-19）患者的多器官功能衰竭是一个严重的问题，可能导致致命的后果。器官和组织损伤，包括一般的肺功能障碍，是由于小血管血栓形成和缺氧导致的缺血引起的，这反过来又会导致氧化应激和炎症。目前，正在筛选具有抗氧化、抗血小板和抗炎特性的现有药物。我们研究了有关 COVID-19 患者组织和器官损伤机制以及现有治疗策略的现有文献，提出研究水杨酰-卡尼汀作为 COVID-19 患者潜在治疗药物的可能性。在最近的一项研究中，我们描述了该药物的合成过程，并表明水杨酰-卡尼汀具有抗氧化、抗炎和抗血小板作用。因此，它可以同时作用于 COVID-19 中涉及组织和器官损伤的三个发病因素。因此，我们建议将水杨酰-卡尼汀作为治疗严重 COVID-19 感染患者的潜在药物进行考虑。
